載入中
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
前收盤價
US$12.67
+US$0.28 · +2.26%
盤中時間採用ET。市場資料可能有所延遲。
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
日內區間
目前US$12.67
52週區間
目前US$12.67
盤中時間採用ET。市場資料可能有所延遲。
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
日內區間
目前US$12.67
52週區間
目前US$12.67
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 9998.6萬 USD | 7990.6萬 USD | 6542.1萬 USD | 4552萬 USD | 4518.3萬 USD |
| 銷貨成本 | 2276.6萬 USD | 2082.1萬 USD | 1729.9萬 USD | 1302.7萬 USD | 1174.8萬 USD |
| 毛利 | 7722萬 USD | 5908.5萬 USD | 4812.2萬 USD | 3249.3萬 USD | 3343.5萬 USD |
| 研究與開發 | 2788.8萬 USD | 2365.3萬 USD | 2077.8萬 USD | 2194.6萬 USD | 1821.1萬 USD |
| 銷售、一般及管理費用 | 6567萬 USD | 5710.3萬 USD | 5451.8萬 USD | 5134.1萬 USD | 3896.1萬 USD |
| 營業費用 | 9355.8萬 USD | 8075.6萬 USD | 7529.6萬 USD | 7328.7萬 USD | 5717.2萬 USD |
| 利息收入 | 281.6萬 USD | 302.4萬 USD | 305萬 USD | 157.8萬 USD | 44.8萬 USD |
| 利息支出 | 745.7萬 USD | 879.8萬 USD | 851.7萬 USD | 752.9萬 USD | 741萬 USD |
| 折舊和攤銷 | 194.8萬 USD | 176.9萬 USD | 160.5萬 USD | 298.7萬 USD | 29.6萬 USD |
| 營業利益 | −1633.8萬 USD | −2167.1萬 USD | −2717.4萬 USD | −4079.4萬 USD | −2373.7萬 USD |
| 淨利 | −2146.5萬 USD | −2714.1萬 USD | −3295.6萬 USD | −4708.2萬 USD | −3608萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1330.92萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM871.98萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF432.28萬0.00%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO294.88萬0.02%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO223.16萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC102.86萬0.08%13.17億 USD0.60%US$183+0.11%
State Street SPDR S&P Health Care Equipment ETFXHE58.73萬0.34%1.74億 USD0.35%US$89.47+1.51%
Vanguard Russell 2000 Growth ETFVTWG42萬0.02%17億 USD0.06%US$260.49+0.91%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCState Street SPDR S&P Health Care Equipment ETFXHEVanguard Russell 2000 Growth ETFVTWGAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
